D-0337-2021 Class II Terminated

Recalled by Noven Pharmaceuticals Inc — Miami, FL

FDA drug recall D-0337-2021 was initiated by Noven Pharmaceuticals Inc on Apr 16, 2021 and is designated Class II. Reason for recall: Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience… The recall status is terminated (terminated Oct 11, 2024). Affected quantity: 10872 cartons.

Recall details

Product Type
Drugs
Report Date
Apr 28, 2021
Initiation Date
Apr 16, 2021
Termination Date
Oct 11, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
10872 cartons

Product description

Estradiol Transdermal System Delivers 0.0375 mg/day, 8 Systems/box, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. by: Noven Therapeutics, LLC Miami, Florida 33186, NDC 68968-3437-8

Reason for recall

Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Distribution pattern

Nationwide within the United States

Code information

Lot #: 88321 Exp. 02/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0337-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0337-2021. Report a data issue: hello@regdatalab.com.